Company intelligence / Profile preview
Bitterroot Bio
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
Overview
Bitterroot Bio has initiated a Phase 1 clinical trial of its lead candidate BRB‑002, targeting the CD47/SIRPα pathway for atherosclerosis and vascular inflammation. Preclinical data demonstrated efficacy and safety in animal models. The company is now evaluating safety and tolerability in healthy volunteers, with plans to advance to proof-of-concept studies in patients with cardiovascular disease[7].
- Therapeutic areas
- Cardiovascular
- Modalities
- Protein therapiesImmune cell therapy[6]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Bitterroot Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bitterroot Bio.